Lucid Diagnostics price target raised to $2.50 from $2 at BTIG

BTIG analyst Mark Massaro raised the firm’s price target on Lucid Diagnostics (LUCD) to $2.50 from $2 and keeps a Buy rating on the shares. Attending the CMS meeting to discuss the merits of Medicare coverage for Lucid’s EsoGuard test, the firm heard “unanimously positive statements” from all clinicians supporting the “obvious use case” for EsoGuard, the analyst tells investors in a research note.